JP2009534440A - カリウムチャンネルモジュレーターとしてのcbxカンナビノイド受容体モジュレーターの使用 - Google Patents
カリウムチャンネルモジュレーターとしてのcbxカンナビノイド受容体モジュレーターの使用 Download PDFInfo
- Publication number
- JP2009534440A JP2009534440A JP2009507043A JP2009507043A JP2009534440A JP 2009534440 A JP2009534440 A JP 2009534440A JP 2009507043 A JP2009507043 A JP 2009507043A JP 2009507043 A JP2009507043 A JP 2009507043A JP 2009534440 A JP2009534440 A JP 2009534440A
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- chloro
- carboxylic acid
- dichloro
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06113190 | 2006-04-27 | ||
PCT/EP2007/053915 WO2007125049A1 (fr) | 2006-04-27 | 2007-04-20 | Utilisation de modulateurs de récepteurs aux cannabinoïdes cbx en tant que modulateurs de canaux potassium |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2009534440A true JP2009534440A (ja) | 2009-09-24 |
Family
ID=36808728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009507043A Pending JP2009534440A (ja) | 2006-04-27 | 2007-04-20 | カリウムチャンネルモジュレーターとしてのcbxカンナビノイド受容体モジュレーターの使用 |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2012775A1 (fr) |
JP (1) | JP2009534440A (fr) |
CN (1) | CN101431994A (fr) |
AR (1) | AR060626A1 (fr) |
AU (1) | AU2007245734A1 (fr) |
CA (1) | CA2650567A1 (fr) |
MX (1) | MX2008013285A (fr) |
RU (1) | RU2008146591A (fr) |
TW (1) | TW200812576A (fr) |
WO (1) | WO2007125049A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013047701A1 (fr) * | 2011-09-29 | 2013-04-04 | 小野薬品工業株式会社 | Dérivé phényle |
JP2015521193A (ja) * | 2012-05-31 | 2015-07-27 | フェネックス ファーマシューティカルス アーゲー | オーファン核内受容体RORγの調整剤としてのカルボキサミドまたはスルホンアミド置換されたチアゾールおよび関連する誘導体 |
US9676719B2 (en) | 2013-03-26 | 2017-06-13 | Ono Pharmaceutical Co., Ltd. | Phenyl derivative |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200827346A (en) | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
TW200836719A (en) | 2007-02-12 | 2008-09-16 | Astrazeneca Ab | Chemical compounds |
AU2011329636B2 (en) * | 2010-11-18 | 2016-05-19 | Jenrin Discovery | Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
CN106138053B (zh) * | 2015-04-28 | 2019-04-09 | 上海市同济医院 | 一种化合物在制备治疗帕金森病的药物中的应用 |
EP3109237A1 (fr) | 2015-06-22 | 2016-12-28 | AnaMar AB | Nouveaux antagonistes de 5-ht2 |
WO2021087127A1 (fr) * | 2019-10-29 | 2021-05-06 | Corbus Pharmaceuticals, Inc. | Cannabinoïdes et utilisations associées |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003063758A2 (fr) * | 2002-01-31 | 2003-08-07 | Pharmos Corporation | Ligands du recepteur cannabinoide cb2 bicyclique |
GB0402356D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
-
2007
- 2007-04-20 AU AU2007245734A patent/AU2007245734A1/en not_active Abandoned
- 2007-04-20 CA CA002650567A patent/CA2650567A1/fr not_active Abandoned
- 2007-04-20 EP EP07728372A patent/EP2012775A1/fr not_active Withdrawn
- 2007-04-20 RU RU2008146591/15A patent/RU2008146591A/ru not_active Application Discontinuation
- 2007-04-20 MX MX2008013285A patent/MX2008013285A/es not_active Application Discontinuation
- 2007-04-20 WO PCT/EP2007/053915 patent/WO2007125049A1/fr active Application Filing
- 2007-04-20 CN CNA2007800151866A patent/CN101431994A/zh active Pending
- 2007-04-20 JP JP2009507043A patent/JP2009534440A/ja active Pending
- 2007-04-23 AR ARP070101748A patent/AR060626A1/es unknown
- 2007-04-26 TW TW096114781A patent/TW200812576A/zh unknown
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013047701A1 (fr) * | 2011-09-29 | 2013-04-04 | 小野薬品工業株式会社 | Dérivé phényle |
KR20140077891A (ko) * | 2011-09-29 | 2014-06-24 | 오노 야꾸힝 고교 가부시키가이샤 | 페닐 유도체 |
US8975409B2 (en) | 2011-09-29 | 2015-03-10 | Ono Pharmaceutical Co., Ltd. | Phenyl derivative |
JPWO2013047701A1 (ja) * | 2011-09-29 | 2015-03-26 | 小野薬品工業株式会社 | フェニル誘導体 |
US9340499B2 (en) | 2011-09-29 | 2016-05-17 | Ono Pharmaceutical Co., Ltd. | Phenyl derivative |
JP2017036309A (ja) * | 2011-09-29 | 2017-02-16 | 小野薬品工業株式会社 | フェニル誘導体 |
US9820980B2 (en) | 2011-09-29 | 2017-11-21 | Ono Pharmaceutical Co., Ltd. | Phenyl derivative |
US10117861B2 (en) | 2011-09-29 | 2018-11-06 | Ono Pharmaceutical Co., Ltd. | Phenyl derivative |
KR101972619B1 (ko) | 2011-09-29 | 2019-04-25 | 오노 야꾸힝 고교 가부시키가이샤 | 페닐 유도체 |
US10835520B2 (en) | 2011-09-29 | 2020-11-17 | Ono Pharmaceutical Co., Ltd. | Phenyl derivative |
JP2015521193A (ja) * | 2012-05-31 | 2015-07-27 | フェネックス ファーマシューティカルス アーゲー | オーファン核内受容体RORγの調整剤としてのカルボキサミドまたはスルホンアミド置換されたチアゾールおよび関連する誘導体 |
US9676719B2 (en) | 2013-03-26 | 2017-06-13 | Ono Pharmaceutical Co., Ltd. | Phenyl derivative |
Also Published As
Publication number | Publication date |
---|---|
CA2650567A1 (fr) | 2007-11-08 |
EP2012775A1 (fr) | 2009-01-14 |
AU2007245734A1 (en) | 2007-11-08 |
WO2007125049A1 (fr) | 2007-11-08 |
RU2008146591A (ru) | 2010-06-10 |
TW200812576A (en) | 2008-03-16 |
CN101431994A (zh) | 2009-05-13 |
AR060626A1 (es) | 2008-07-02 |
MX2008013285A (es) | 2008-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7763607B2 (en) | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | |
JP2009534440A (ja) | カリウムチャンネルモジュレーターとしてのcbxカンナビノイド受容体モジュレーターの使用 | |
US8058264B2 (en) | Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions | |
US20070254863A1 (en) | Use of CBx cannabinoid receptor modulators as potassium channel modulators | |
Lopez-Parra et al. | Fcγ receptor deficiency attenuates diabetic nephropathy | |
EA012600B1 (ru) | Применение антагониста рецептора ангиотензина ii телмисартана для повышения чувствительности к инсулину | |
US8604060B2 (en) | Use of antagonists of the CBI receptor for the manufacture of a composition useful for the treatment of hepatic diseases | |
JP2009534439A (ja) | Cbxカンナビノイド受容体モジュレータ及びカリウムチャンネルモジュレータを含む医薬組成物 | |
US20120142638A1 (en) | Combination of organic compounds | |
JP2009501192A (ja) | 有機化合物の組み合わせ | |
Yamada et al. | Mechanism underlying the efficacy of combination therapy with losartan and hydrochlorothiazide in rats with salt-sensitive hypertension | |
EP0635263A2 (fr) | Antagonistes de l'angiotensine II (AII) comme inhibiteurs de la croissance du tissu adipeux | |
EP3858339A1 (fr) | Inhibiteur de canal d'ion trpm-4 pour le traitement ou la prévention de la sclérose en plaques | |
KR20070070226A (ko) | 타입 ⅰ 당뇨, 비만 및 관련된 증상의 치료를 위한 cb1칸나비노이드 수용체 길항제 및 포타슘 채널 오프너를포함하는 약학적 조성물 | |
CN101048153A (zh) | 用于治疗ⅰ型糖尿病、肥胖和相关疾病的包含cb1大麻素受体拮抗剂和钾通道开放剂的药物组合物 | |
SAMSON | Sudden Falls During Some Seizures May Be Heart Related |